Navigation Links
Perrigo Settles Desloratadine Patent Litigation
Date:12/4/2008

ALLEGAN, Mich., Dec. 4 /PRNewswire-FirstCall/ -- The Perrigo Company (Nasdaq: PRGO; TASE) announced today that all Hatch-Waxman litigation relating to Desloratadine tablets (5 mg) has been settled with Perrigo taking a license under all relevant patents. Perrigo had been sued for patent infringement of US Patent Nos. 6100274, 7214683 and 7214684 based upon its filing of an ANDA containing a Paragraph IV certification. Under the terms of the settlement, Perrigo can commercially launch its generic Desloratadine product on July 1, 2012, or earlier in certain circumstances. The new product launch may be a prescription or over-the-counter (OTC) product depending on its status at the time of launch. The Perrigo product is awaiting FDA approval.

This product seeks an AB-rating as equivalent to Schering-Plough's Clarinex(R) tablets (5 mg) indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis and chronic idiopathic urticaria. Sales for the brand were approximately $300 million, according to Wolters Kluwer data for the twelve months ending October 2008.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This is another example of Perrigo's continued commitment to bring new products to the market. Perrigo continues to be focused on our mission of making quality healthcare more affordable for consumers."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 28, 2008, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Arthur J. Shannon, Vice President, Investor Relations and Communication

(269) 686-1709

E-mail: ajshannon@perrigo.com


'/>"/>
SOURCE Perrigo Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Acknowledges Settlement of NASACORT(R) AQ Nasal Spray Patent Litigation
2. Perrigo Announces FDA Tentative Approval for Ibuprofen PM
3. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
4. Perrigo Company To Present at the Merrill Lynch Global Pharmaceutical Conference
5. Perrigo Begins Shipments of Famotidine Complete to Customers Nationwide
6. Perrigo Company Announces Appointment of New Board Member
7. Perrigo Company to Present at The Oppenheimer & Co. Inc. 8th Annual Consumer Growth Conference
8. Perrigo Announces Approval for Rx Cetirizine Syrup
9. Perrigo Confirms Filing for Generic Version of VANOS(R)
10. Perrigo Company Announces Collaborative Agreement for Generic Topical Products With Pentech
11. Perrigo Company to Present at the Citi Investment Research Global Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon Kleyne is ... product of her research center at Bio-Logic Aqua Research® Water Life Science®, has ... greatest number of sufferers of blindness. “We think that Nature’s Tears® EyeMist® will ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... (PRWEB) , ... July 20, ... ... provider of enterprise-grade IT operations analytics and application performance monitoring (APM) solutions, ... world’s largest healthcare services providers. , According to Peter Ohrenberger, sales director ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... Team Type ... access to medicine for everyone affected by diabetes, is teaming up with a Microsoft ... global event kicks off on July 24th. , “Team Type 1’s mission overlaps ...
(Date:7/20/2017)... ... July 20, 2017 , ... Using ... Aug. 9, 2017 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/mdqualitydata          ... boosting quality. , It’s known as the “CY2016 Annual FDA Medical Device Quality ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... (FDA) has agreed to schedule an End-of-Phase II meeting ... of its oral insulin capsule ORMD-0801 in the treatment ... primary and secondary endpoints by indicating a statistically significant ...
(Date:7/10/2017)... July 10, 2017 Locus Biosciences Inc. today ... support the development of CRISPR-Cas3 antimicrobial therapeutics. Financing for ... leading Chinese Internet services provider, and joined by the ... infectious disease product programs targeting antibiotic resistant infections and ... Founded by Dr. Rodolphe Barrangou and Dr. ...
(Date:7/5/2017)... BOTHELL, Wash. , July 5, 2017   ... a leading developer, manufacturer and marketer of proprietary clinical ... cryopreservation freeze media ("BioLife"), today announced that ... ("WAVI") its debt holder and largest shareholder, to modify ... Pursuant to the modification, WAVI agreed to ...
Breaking Medicine Technology: